141 related articles for article (PubMed ID: 15681812)
1. The role of alpha-synuclein in both neuroprotection and neurodegeneration.
Sidhu A; Wersinger C; Moussa CE; Vernier P
Ann N Y Acad Sci; 2004 Dec; 1035():250-70. PubMed ID: 15681812
[TBL] [Abstract][Full Text] [Related]
2. Does alpha-synuclein modulate dopaminergic synaptic content and tone at the synapse?
Sidhu A; Wersinger C; Vernier P
FASEB J; 2004 Apr; 18(6):637-47. PubMed ID: 15054086
[TBL] [Abstract][Full Text] [Related]
3. Dopamine-dependent neurotoxicity of alpha-synuclein: a mechanism for selective neurodegeneration in Parkinson disease.
Xu J; Kao SY; Lee FJ; Song W; Jin LW; Yankner BA
Nat Med; 2002 Jun; 8(6):600-6. PubMed ID: 12042811
[TBL] [Abstract][Full Text] [Related]
4. alpha-Synuclein regulation of the dopaminergic transporter: a possible role in the pathogenesis of Parkinson's disease.
Sidhu A; Wersinger C; Vernier P
FEBS Lett; 2004 May; 565(1-3):1-5. PubMed ID: 15135042
[TBL] [Abstract][Full Text] [Related]
5. Disruption of dopamine homeostasis underlies selective neurodegeneration mediated by alpha-synuclein.
Park SS; Schulz EM; Lee D
Eur J Neurosci; 2007 Dec; 26(11):3104-12. PubMed ID: 18005066
[TBL] [Abstract][Full Text] [Related]
6. Alpha-synuclein aggregation and cell death triggered by energy deprivation and dopamine overload are counteracted by D2/D3 receptor activation.
Bellucci A; Collo G; Sarnico I; Battistin L; Missale C; Spano P
J Neurochem; 2008 Jul; 106(2):560-77. PubMed ID: 18410503
[TBL] [Abstract][Full Text] [Related]
7. Lentiviral nigral delivery of GDNF does not prevent neurodegeneration in a genetic rat model of Parkinson's disease.
Lo Bianco C; Déglon N; Pralong W; Aebischer P
Neurobiol Dis; 2004 Nov; 17(2):283-9. PubMed ID: 15474365
[TBL] [Abstract][Full Text] [Related]
8. Wild-type alpha-synuclein interacts with pro-apoptotic proteins PKCdelta and BAD to protect dopaminergic neuronal cells against MPP+-induced apoptotic cell death.
Kaul S; Anantharam V; Kanthasamy A; Kanthasamy AG
Brain Res Mol Brain Res; 2005 Sep; 139(1):137-52. PubMed ID: 15978696
[TBL] [Abstract][Full Text] [Related]
9. Wild-type and mutant alpha-synuclein induce a multi-component gene expression profile consistent with shared pathophysiology in different transgenic mouse models of PD.
Miller RM; Kiser GL; Kaysser-Kranich T; Casaceli C; Colla E; Lee MK; Palaniappan C; Federoff HJ
Exp Neurol; 2007 Mar; 204(1):421-32. PubMed ID: 17254569
[TBL] [Abstract][Full Text] [Related]
10. Microarray expression analysis of human dopaminergic neuroblastoma cells after RNA interference of SNCA--a key player in the pathogenesis of Parkinson's disease.
Häbig K; Walter M; Stappert H; Riess O; Bonin M
Brain Res; 2009 Feb; 1256():19-33. PubMed ID: 19135032
[TBL] [Abstract][Full Text] [Related]
11. A chemical chaperone, sodium 4-phenylbutyric acid, attenuates the pathogenic potency in human alpha-synuclein A30P + A53T transgenic mice.
Ono K; Ikemoto M; Kawarabayashi T; Ikeda M; Nishinakagawa T; Hosokawa M; Shoji M; Takahashi M; Nakashima M
Parkinsonism Relat Disord; 2009 Nov; 15(9):649-54. PubMed ID: 19345133
[TBL] [Abstract][Full Text] [Related]
12. Differential effects of overexpression of wild-type and mutant human alpha-synuclein on MPP+-induced neurotoxicity in PC12 cells.
Qian JJ; Cheng YB; Yang YP; Mao CJ; Qin ZH; Li K; Liu CF
Neurosci Lett; 2008 Apr; 435(2):142-6. PubMed ID: 18342443
[TBL] [Abstract][Full Text] [Related]
13. Alpha-synuclein protects cerebellar granule neurons against 6-hydroxydopamine-induced death.
Monti B; Polazzi E; Batti L; Crochemore C; Virgili M; Contestabile A
J Neurochem; 2007 Oct; 103(2):518-30. PubMed ID: 17635667
[TBL] [Abstract][Full Text] [Related]
14. Dieldrin induces ubiquitin-proteasome dysfunction in alpha-synuclein overexpressing dopaminergic neuronal cells and enhances susceptibility to apoptotic cell death.
Sun F; Anantharam V; Latchoumycandane C; Kanthasamy A; Kanthasamy AG
J Pharmacol Exp Ther; 2005 Oct; 315(1):69-79. PubMed ID: 15987830
[TBL] [Abstract][Full Text] [Related]
15. Axonal alpha-synuclein aggregates herald centripetal degeneration of cardiac sympathetic nerve in Parkinson's disease.
Orimo S; Uchihara T; Nakamura A; Mori F; Kakita A; Wakabayashi K; Takahashi H
Brain; 2008 Mar; 131(Pt 3):642-50. PubMed ID: 18079166
[TBL] [Abstract][Full Text] [Related]
16. Disruption of the interaction of alpha-synuclein with microtubules enhances cell surface recruitment of the dopamine transporter.
Wersinger C; Sidhu A
Biochemistry; 2005 Oct; 44(41):13612-24. PubMed ID: 16216085
[TBL] [Abstract][Full Text] [Related]
17. Impairment of redox state and dopamine level induced by alpha-synuclein aggregation and the prevention effect of hsp70.
Yu F; Xu H; Zhuo M; Sun L; Dong A; Liu X
Biochem Biophys Res Commun; 2005 May; 331(1):278-84. PubMed ID: 15845390
[TBL] [Abstract][Full Text] [Related]
18. Dopamine transporter-mediated cytotoxicity of 6-hydroxydopamine in vitro depends on expression of mutant alpha-synucleins related to Parkinson's disease.
Lehmensiek V; Tan EM; Liebau S; Lenk T; Zettlmeisl H; Schwarz J; Storch A
Neurochem Int; 2006 Apr; 48(5):329-40. PubMed ID: 16406146
[TBL] [Abstract][Full Text] [Related]
19. Occurrence of neuronal inclusions combined with increased nigral expression of alpha-synuclein within dopaminergic neurons following treatment with amphetamine derivatives in mice.
Fornai F; Lenzi P; Ferrucci M; Lazzeri G; di Poggio AB; Natale G; Busceti CL; Biagioni F; Giusiani M; Ruggieri S; Paparelli A
Brain Res Bull; 2005 May; 65(5):405-13. PubMed ID: 15833595
[TBL] [Abstract][Full Text] [Related]
20. Alpha-synuclein expression in the substantia nigra of MPTP-lesioned non-human primates.
Purisai MG; McCormack AL; Langston WJ; Johnston LC; Di Monte DA
Neurobiol Dis; 2005 Dec; 20(3):898-906. PubMed ID: 16006134
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
